A summary of meeting proceedings on addressing variability around the cut point in serial interferon-γ release assay testing

Infection Control and Hospital Epidemiology

Volumn 34, Issue 6, 2013, Pages 625-630

  Daley, Charles L ^a,b   Reves, Randall R ^b,c   Beard, Melodie A ^d   Boyle, Jeffrey ^e   Clark, Richard B ^f   Beebe, James L ^g   Catanzaro, Antonino ^h   Chen, Lisa ⁱ   Desmond, Edward ^j   Dorman, Susan E ^k   Hudson, T Warner ^l   Lardizabal, Alfred A ^m   Kapoor, Hema ^f   Marder, David C ⁿ   Miranda, Cyndee ^o   Narita, Masahiro ^p   Reichman, Lee ^m   Schwab, Dale ^f   Seaworth, Barbara J ^q   Terpeluk, Paul ^o   Thanassi, Wendy ^r   Kawamura, L Masae ^e   more..

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c DENVER PUBLIC HEALTH   (United States)

^d LABORATORY CORPORATION OF AMERICA   (United States)

^e Cellestis QIAGEN ^*  (United States)

^f QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^g San Luis Obispo Oncology and Hematology Health Center   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l American College of Occupational and Environmental Medicine   (United States)

^m RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^o LERNER RESEARCH INSTITUTE   (United States)

^p UNIVERSITY OF WASHINGTON   (United States)

^q University of Texas Health Science Center   (United States)

^r STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

CD4 LYMPHOCYTE COUNT; COST BENEFIT ANALYSIS; DISEASE CONTROL; DISEASE COURSE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MEDICAL RECORD REVIEW; PATIENT CARE; PROPHYLAXIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK FACTOR; TUBERCULIN TEST; TUBERCULOSIS; VIRUS LOAD;

HEALTH CARE SECTOR; HUMANS; INTERFERON-GAMMA RELEASE TESTS; OCCUPATIONAL HEALTH; PRACTICE GUIDELINES AS TOPIC; ROC CURVE; TUBERCULOSIS; UNITED STATES;

EID: 84877668913     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/670635     Document Type: Review

References (14)

1. Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010;59(RR-5):1-25.
2. Medical Center Occupational Health Section and Occupational and Environmental Lung Disorders Committee. Protecting' health care workers from tuberculosis. J Occup Environ Med 2008;50:852-855.
3. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med 2006;3:e494.
4. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 2012;67: 62-70.
5. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS ONE 2009;4(12):e8517.
6. Ringshausen F, Schablon A, Nienhaus A. Interferon-gamma release assays for the tuberculosis serial testing of healthcare workers: a systematic review. J Occup Med Toxic 2012;7:6.
7. Sahni R, Miranda C, Yen-Lieberman B, et al. Does the implementation of an interferon-y release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers? Infect Control Hosp Epidemiol 2009;30:197-199.
8. Fong K, Tomford JW, Teixeira L, et al. Challenges of interferon-7 release assay conversions in serial testing of health-care workers in a TB control program. Chest 2012;142:55-62.
9. Talati NJ, Seybold U, Humphrey B, et al. Poor concordance between interferon-7 release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009;9:15.
10. Gray J, Belknap R, Reves R, et al. Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis. Clin Infect Dis 2012; 54(3):e20-e23.
11. Kraemer HC. Evaluating Medical Tests: Objective and Quantitative Guidelines. Newbury Park, CA: Sage, 1992.
12. Veerapathran A, Joshi R, Goswami K, et al. T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. PLoS ONE 2008;3:e1850.
13. van Zyl-Smit RN, Pai M, Dheda K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009;180: 49-58.
14. QuantiFERON-TB Gold [package insert]. Chadstone, Australia: Cellestis, 2011. http://www.cellestis.com/IRM/content/pdf/39111_PI_05990301H_AUS_DEC%202011_ttf.pdf.